[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cryopyrin-associated-periodic-syndromes-caps\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cryopyrin-associated-periodic-syndromes-caps":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100580503","ilaris-nis-in-korea-100580503",false,"NCT06838143","Ilaris NIS in Korea","Real Life Non-interventional Study on Safety and Effectiveness of Ilaris® (Canakinumab) 150 mg for Subcutaneous Injection in Hereditary Periodic Fever Syndrome (CAPS, crFMF, TRAPS and HIDS\u002FMKD) Patients and sJIA Patients (REASSURE)","REASSURE","Inclusion Criteria:\n\n1. Written informed consent\u002Fassent of the patient or their legal representative\u002Fparent (≥2 year and \\\u003C19 year-old pediatric patient) for voluntarily participating in this study\n2. Age: ≥2 year and \\\u003C19 year-old pediatric and ≥19 year-old adult hereditary periodic fever syndrome (CAPS, crFMF, TRAPS and HIDS\u002FMKD) patients and ≥2 year and \\\u003C19 year-old sJIA patients\n3. Patient who have an agreement to be treated or who have already started treatment with Ilaris in accordance with the approved label information\n\nExclusion Criteria:\n\n1. Patients receiving Ilaris treatment for autoimmune disease other than CAPS, crFMF, TRAPS, HIDS\u002FMKD or sJIA\n2. Patients participating in an interventional clinical trial which would have an impact on routine clinical treatment","ALL","2 Years","100 Years",{"count":21,"type":22},25,"ESTIMATED","OBSERVATIONAL","This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes, Cryopyrin-associated periodic syndromes (CAPS), colchicine resistance familial Mediterranean fever (crFMF), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome \u002F Mevalonate kinase deficiency (HIDS\u002FMKD) or Systemic juvenile idiopathic arthritis (sJIA).",[26,27,28,29,30,31],"Hereditary Periodic Fever Syndromes","Cryopyrin-associated Periodic Syndromes (CAPS)","Colchicine Resistance Familial Mediterranean Fever (crFMF)","TNF Receptor Associated Periodic Syndrome (TRAPS)","Hyper-IgD Syndrome \u002F Mevalonate Kinase Deficiency (HIDS\u002FMKD)","Systemic Juvenile Idiopathic Arthritis (sJIA)",[26,33,34,35,36,37],"Cryopyrin-associated periodic syndromes (CAPS)","colchicine resistance familial Mediterranean fever (crFMF)","TNF receptor associated periodic syndrome (TRAPS)","Hyper-IgD syndrome \u002F Mevalonate kinase deficiency (HIDS\u002FMKD)","Systemic juvenile idiopathic arthritis (sJIA)","RECRUITING","2026-05-15",{"date":41,"type":42},"2026-05-19","ACTUAL",{"date":44,"type":42},"2025-03-29",{"date":46,"type":22},"2028-09-30",{"name":48,"class":49},"Novartis Pharmaceuticals","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":50},"100611952","phase-1-study-to-evaluate-the-safety-tolerability-efficacy-and-pharmacokinetics-of-jte-162-in-subjects-with-cryopyrin-associated-periodic-syndrome-caps-100611952","NCT07247266","Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)","A Phase 1b, Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)","Inclusion Criteria:\n\n* Diagnosed with familial cold autoinflammatory syndrome (FCAS) or Muckle-Wells syndrome (MWS) confirmed by:\n* Clinical History: At least 2 typical clinical symptoms (e.g., urticarial skin rash, myalgia, arthralgia, recurrent fever, fatigue\u002Fmalaise, conjunctivitis or other autoinflammatory symptoms) prior to the Screening Visit; AND\n* Genetic Confirmation: Confirmed nucleotide-binding and oligomerization domain (NOD)-like receptor family pyrin domain containing 3 (NLRP3) mutation;\n* Willing to discontinue current anti-interleukin (IL)-1 treatment, if applicable;\n* Demonstrates de novo flaring of CAPS during the Screening Period.\n\nExclusion Criteria:\n\n* Has chronic infantile neurologic cutaneous articular syndrome (CINCA)\u002Fneonatal-onset multisystem inflammatory disease (NOMID);\n* Has a history or presence of amyloidosis, progressive hearing loss, organ damage or any symptom contraindicating anti-IL-1 treatment washout;\n* Has active systemic bacterial, fungal or viral infection(s) within 14 days prior to Day 1 or a history of clinically significant recurrent infectious diseases","18 Years","80 Years",{"count":61,"type":22},5,"INTERVENTIONAL",[64],"PHASE1","This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)",[27],[68,69,70,71,72,73,74],"JTE-162","Efficacy","Safety","Tolerability","Cryopyrin-associated periodic syndromes","CAPS","Pharmacokinetics","2026-02-05",{"date":77,"type":42},"2026-02-09",{"date":79,"type":42},"2026-02-02",{"date":81,"type":22},"2026-12",{"name":83,"class":49},"Akros Pharma Inc."]